Bellevue Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bellevue Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Hold	1,016	–	–	﹤0.01%	132
2026 Q1	$88.4K	Sell	1,016 -6,488	-86%	-$631K	﹤0.01%	141
2025 Q4	$803K	Sell	7,504 -1,549	-17%	-$164K	0.02%	116
2025 Q3	$914K	Sell	9,053 -11,853	-57%	-$1.1M	0.02%	108
2025 Q2	$1.32M	Buy	20,906 +5,356	+34%	+$328K	0.03%	102
2025 Q1	$824K	Sell	15,550 -8,046	-34%	-$446K	0.02%	110
2024 Q4	$1.32M	Buy	23,596 +7,896	+50%	+$436K	0.03%	113
2024 Q3	$823K	Buy	15,700 +2,700	+21%	+$129K	0.01%	123
2024 Q2	$534K	Buy	13,000 +500	+4%	+$20K	0.01%	127
2024 Q1	$542K	Sell	12,500 -20,369	-62%	-$891K	0.01%	128
2023 Q4	$1.51M	Sell	32,869 -40,431	-55%	-$1.28M	0.02%	114
2023 Q3	$1.68M	Buy	+73,300	New	+$1.64M	0.03%	115

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group's RYTM Position: Q2 2026 in Review

Bellevue Group held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 1,016 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #132.

Bellevue Group first reported a position in RYTM in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.68M in Q3 2023. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Bellevue Group held 1,016 shares of Rhythm Pharmaceuticals worth $113K as of Q2 2026.
Bellevue Group left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #132 holding.
Bellevue Group first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Bellevue Group's Rhythm Pharmaceuticals position peaked at $1.68M in Q3 2023.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.